MIRAE ASSET
HEALTHCARE FUND - (MAHCF)
(An open ended equity scheme investing in healthcare and allied sectors)
| Type of Scheme | Healthcare Fund - An open ended equity scheme investing in healthcare and allied sectors |
| Investment Objective | The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns. |
Fund Manager** |
Mr. Vrijesh Kasera (since 02nd July, 2018) |
| Allotment Date | 02nd July, 2018 |
| Benchmark Index | S&P BSE Healthcare Index (TRI) |
| Minimum Investment Amount |
₹ 5,000/- and in multiples of ₹ 1/-thereafter. Minimum Additional Application Amount: ₹ 1,000/- per application and in multiples of ₹ 1/- thereafter. |
Systematic Investment Plan (SIP) (Any Date SIP is available from 1st July, 2019) |
Monthly and Quarterly: ₹ 1,000/- (multiples of ₹ 1/- thereafter), minimum 5 installments |
| Load Structure | Entry load: NA Exit load: I. For investors who have opted for SWP under the plan: a) 15% of the units allotted (including Switch-in/STP - in) on or before completion of 365 days from the date of allotment of units: Nil. b) Any redemption in excess of such limits in the first 365 days from the date of allotment shall be subject to the following exit load: (Redemption of units would be done on First In First Out Basis (FIFO): •If redeemed within 1 year (365 days) from the date of allotment: 1% •If redeemed after 1 year (365 days) from the date of allotment: NIL II. Other Redemptions: For Investors who have not opted for SWP under the plan (including Switch out, STP out): •If redeemed within 1 year (365 days) from the date of allotment: 1% •If redeemed after 1 year (365 days) from the date of allotment: NIL |
| Plans Available | Regular Plan and Direct Plan |
| Options Available | Growth Option and Dividend Option (Payout & Re-investment) |
| Monthly Average AUM (₹ Cr.) as on August 31, 2020 |
860.76 |
| Net AUM (₹ Cr.) | 876.08 |
| Monthly Avg. Expense Ratio (Including Statutory Levies) as on August 31, 2020 |
Regular Plan: 2.42% Direct Plan: 0.75% |
| ANY DATE SIP provides one of the better investment experiences by allowing the investor to choose any investment date of the month (i.e., from 1st to 28th) depending upon the investors' expense and income flow. | |
| **For experience of Fund Managers Click Here | |
| NAV: | Direct Plan | Regular Plan |
| Growth Option | ₹ 16.483 | ₹ 15.917 |
| Dividend Option | ₹ 16.483 | ₹ 15.916 |
| Portfolio Turnover Ratio^ | 0.29 times |
@The Volatility, Beta, R Squared, Sharpe Ratio & Information Ratio are calculated on returns from last three years Monthly data points. # Risk free rate: FBIL OVERNIGHT MIBOR as on 31st August 2020. ^Basis last rolling 12 months. |
|
| Positions Increased |
| Stock |
| Chemicals |
| Rossari Biotech Limited |
| Vinati Organics Limited |
| Finance |
| HDFC Life Insurance Company Limited |
| SBI Life Insurance Company Limited |
| Healthcare Services |
| Apollo Hospitals Enterprise Limited |
| Dr. Lal Path Labs Limited |
| Pharmaceuticals |
| Ajanta Pharma Limited |
| Aurobindo Pharma Limited |
| Cipla Limited |
| Divi's Laboratories Limited |
| Dr. Reddy's Laboratories Limited |
| IPCA Laboratories Limited |
| Laurus Labs Limited |
| Lupin Limited |
| Sun Pharmaceutical Industries Limited |
| Positions Decreased |
| Stock |
| Pharmaceuticals |
| Cadila Healthcare Limited |
| Portfolio Holdings | % Allocation |
| Pharmaceuticals | |
| Sun Pharmaceutical Industries Ltd | 11.08% |
| Dr. Reddy's Laboratories Ltd | 10.67% |
| Divi's Laboratories Ltd | 8.31% |
| Cipla Ltd | 7.75% |
| IPCA Laboratories Ltd | 6.06% |
| Lupin Ltd | 5.45% |
| Aurobindo Pharma Ltd | 5.39% |
| Torrent Pharmaceuticals Ltd | 4.96% |
| Laurus Labs Ltd | 4.08% |
| Biocon Ltd | 3.62% |
| Ajanta Pharma Ltd | 2.95% |
| Syngene International Ltd | 2.53% |
| Abbott India Ltd | 2.52% |
| JB Chemicals & Pharmaceuticals Ltd | 2.13% |
| Alkem Laboratories Ltd | 1.77% |
| Sanofi India Ltd | 1.45% |
| Natco Pharma Ltd | 0.64% |
| Cadila Healthcare Ltd | 0.00% |
| Healthcare Services | |
| Apollo Hospitals Enterprise Ltd | 3.52% |
| Dr. Lal Path Labs Ltd | 2.91% |
| Chemicals | |
| Rossari Biotech Ltd | 1.90% |
| Tata Chemicals Ltd | 1.47% |
| Vinati Organics Ltd | 1.37% |
| Neogen Chemicals Ltd | 0.91% |
| Finance | |
| Max Financial Services Ltd | 1.79% |
| HDFC Life Insurance Company Ltd | 1.51% |
| SBI Life Insurance Company Ltd | 1.42% |
| Industrial Products | |
| SRF Ltd | 1.83% |
| Equity Holding Total | 99.96% |
| Cash & Other Receivables | 0.04% |
| Total | 100.00% |
| Returns (%) | ||||
| 1 Yr | SI | |||
| MAHCF | 55.62 |
23.93 |
||
| Scheme Benchmark* | 43.86 |
14.56 |
||
| Additional Benchmark** | 4.60 |
5.59 |
||
| NAV as on 31st August, 2020 | 15.917 | |||
| Index Value (31st August, 2020) | Index Value of Scheme benchmark is 20670.57 and S&P BSE Sensex (TRI) is 56932.37 | |||
| Allotment Date | 02nd July, 2018 | |||
| Scheme Benchmark | *S&P BSE Healthcare Index (TRI) | |||
| Additional Benchmark | **S&P BSE Sensex (TRI) | |||
Note:1. Different Plans under the scheme has different expense structure. The reference and details provided herein are of Regular Plan - Growth Option
2. Fund manager : Mr. Vrijesh Kasera managing the scheme since July, 2018
3. The scheme is in existence for more than 1 year and less than 3 years.
| Period | Total Amount Invested | Mkt Value as on 31-August-2020 |
SI |
250,000 |
362,795 |
1 Yr |
120,000 |
163,988 |
Returns (%) |
Period |
|
SI |
1yr |
|
Fund Return& (%) |
38.60 |
74.31 |
Benchmark Return& (%) |
28.16 |
64.56 |
Add. Benchmark Return& (%) |
5.79 |
13.78 |
& The SIP returns are calculated by XIRR approach assuming investment of ₹ 10,000/- on the 1st working day of every month.
This product is suitable for investors who are seeking*
• To generate long term capital appreciation
• Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India
• Degree of risk – HIGH
*Investors should consult their financial advisers if they are not clear about the suitability of the product.
Past Performance may or may not be sustained in future.
Note : For computation of since inception returns (%) the allotment NAV has been taken as ₹ 10.00. The performance of other funds managed by the same fund manager is given in the respective page of the schemes 